Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4139-4147

  Adams, Hannah M ^a   Li, Xiang ^a   Mascio, Carmela ^b   Chesnel, Laurent ^b   Palmer, Kelli L ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; BACITRACIN; CARDIOLIPIN SYNTHASE; CEFALOTIN; DAPTOMYCIN; METRONIDAZOLE; RIFAMPICIN; SUROTOMYCIN; SYNTHETASE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; CB-183,315; CYCLOPEPTIDE; LIPOPEPTIDE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL MUTATION; DRUG MECHANISM; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE MUTATION; LACTOBACILLUS PLANTARUM; LIPID COMPOSITION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PHOSPHOLIPID METABOLISM; PLEIOTROPY; PRIORITY JOURNAL; RESTRICTION MAPPING; STOP CODON; VIRUS CULTURE; ANTIBIOTIC RESISTANCE; BIOLOGY; DRUG EFFECTS; ENTEROCOCCUS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MUTATION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CLOSTRIDIUM DIFFICILE; COMPUTATIONAL BIOLOGY; DAPTOMYCIN; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; MUTATION; PEPTIDES, CYCLIC; RESTRICTION MAPPING; VANCOMYCIN RESISTANCE;

EID: 84931292100     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00526-15     Document Type: Article

References (76)

1. Rupnik M, Wilcox MH, Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7:526-536. http://dx.doi.org/10.1038/nrmicro2164.
2. Centers for Disease Control and Prevention. 2014. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance /threat-report-2013. Accessed 17 December 2014.
3. Kelly CP, LaMont JT. 2008. Clostridium difficile-more difficult than ever. N Engl J Med 359:1932-1940. http://dx.doi.org/10.1056/NEJMra0707500.
4. Ghose C. 2013. Clostridium difficile infection in the twenty-first century. Emerg Microbes Infect 2:e62. http://dx.doi.org/10.1038/emi.2013.62.
5. Mascio CT, Chesnel L, Thorne G, Silverman JA. 2014. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 58:3976-3982. http://dx.doi.org/10.1128/AAC.00124-14.
6. Mascio CT, Mortin LI, Howland KT, Van Praagh AD, Zhang S, Arya A, Chuong CL, Kang C, Li T, Silverman JA. 2012. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother 56:5023-5030. http://dx.doi.org/10.1128/AAC.00057-12.
7. th Intersci Conf Antimicrob Agents Chemother (ICAAC).
8. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2012. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother 56:1613-1615. http://dx.doi.org/10.1128/AAC.05655-11.
9. st Intersci Conf Antimicrob Agents Chemother.
10. Tyrrell KL, Citron DM, Warren YA, Fernandez HT, Merriam CV, Goldstein EJ. 2006. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. Antimicrob Agents Chemother 50:2728-2731. http://dx.doi.org/10.1128/AAC.00357-06.
11. Wu X, Cherian PT, Lee RE, Hurdle JG. 2013. The membrane as a target for controlling hypervirulent Clostridium difficile infections. J Antimicrob Chemother 68:806-815. http://dx.doi.org/10.1093/jac/dks493.
12. Lebreton F, Willems RJL, Gilmore MS. 2014. Enterococcus diversity, origins in nature, and gut colonization. In Gilmore MS, Clewell DB, Ike Y, Shankar N (ed), Enterococci: from commensals to leading causes of drug resistant infection. Massachusetts Eye and Ear Infirmary, Boston, MA.
13. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34:1-14. http://dx.doi.org/10.1086/668770.
14. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, National Healthcare Safety Network T, Participating National Healthcare Safety Network Facilities. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hospital Epidemiol 29:996 -1011. http://dx.doi.org/10.1086/591861.
15. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK, Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. 2014. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370:1198-1208. http://dx.doi.org/10.1056/NEJMoa1306801.
16. Snydman DR, Jacobus NV, McDermott LA. 2012. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother 56:3448-3452. http://dx.doi.org/10.1128/AAC.06257-11.
17. Humphries RM, Pollett S, Sakoulas G. 2013. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 26:759-780. http://dx.doi.org/10.1128/CMR.00030-13.
18. Manson JM, Keis S, Smith JMB, Cook GM. 2003. A clonal lineage of VanA-type Enterococcus faecalis predominates in vancomycin-resistant enterococci isolated in New Zealand. Antimicrob Agents Chemother 47: 204-210. http://dx.doi.org/10.1128/AAC.47.1.204-210.2003.
19. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST server: rapid annotations using subsystems technology. BMC Genomics 9:75. http://dx.doi.org/10.1186/1471-2164-9-75.
20. Overbeek R, Olson R, Pusch GD, Olsen GJ, Davis JJ, Disz T, Edwards RA, Gerdes S, Parrello B, Shukla M, Vonstein V, Wattam AR, Xia F, Stevens R. 2014. The SEED and the Rapid Annotation of microbial genomes using Subsystems Technology (RAST). Nucleic Acids Res 42: D206-D214. http://dx.doi.org/10.1093/nar/gkt1226.
21. Paulsen IT, Banerjei L, Myers GS, Nelson KE, Seshadri R, Read TD, Fouts DE, Eisen JA, Gill SR, Heidelberg JF, Tettelin H, Dodson RJ, Umayam L, Brinkac L, Beanan M, Daugherty S, DeBoy RT, Durkin S, Kolonay J, Madupu R, Nelson W, Vamathevan J, Tran B, Upton J, Hansen T, Shetty J, Khouri H, Utterback T, Radune D, Ketchum KA, Dougherty BA, Fraser CM. 2003. Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science 299:2071-2074. http://dx.doi.org/10.1126/science.1080613.
22. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. 2011. Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother 55:3345-3356. http://dx.doi.org/10.1128/AAC.00207-11.
23. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. 2001. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 305:567-580. http://dx.doi.org/10.1006/jmbi.2000.4315.
24. Yu NY, Wagner JR, Laird MR, Melli G, Rey S, Lo R, Dao P, Sahinalp SC, Ester M, Foster LJ, Brinkman FS. 2010. PSORTb 3.0: improved protein subcellular localization prediction with refined localization sub-categories and predictive capabilities for all prokaryotes. Bioinformatics 26:1608-1615. http://dx.doi.org/10.1093/bioinformatics/btq249.
25. Lorenz R, Bernhart SH, Honer Zu Siederdissen C, Tafer H, Flamm C, Stadler PF, Hofacker IL. 2011. ViennaRNA package 2.0. Algorithms Mol Biol 6:26. http://dx.doi.org/10.1186/1748-7188-6-26.
26. Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C, Pang N, Forslund K, Ceric G, Clements J, Heger A, Holm L, Sonnhammer EL, Eddy SR, Bateman A, Finn RD. 2012. The Pfam protein families database. Nucleic Acids Res 40:D290-D301. http://dx.doi.org/10.1093/nar/gkr1065.
27. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeno-Tarraga AM, Wang H, Holden MT, Wright A, Churcher C, Quail MA, Baker S, Bason N, Brooks K, Chillingworth T, Cronin A, Davis P, Dowd L, Fraser A, Feltwell T, Hance Z, Holroyd S, Jagels K, Moule S, Mungall K, Price C, Rabbinowitsch E, Sharp S, Simmonds M, Stevens K, Unwin L, Whithead S, Dupuy B, Dougan G, Barrell B, Parkhill J. 2006. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 38:779-786. http://dx.doi.org/10.1038/ng1830.
28. Monot M, Boursaux-Eude C, Thibonnier M, Vallenet D, Moszer I, Medigue C, Martin-Verstraete I, Dupuy B. 2011. Reannotation of the genome sequence of Clostridium difficile strain 630. J Med Microbiol 60: 1193-1199. http://dx.doi.org/10.1099/jmm.0.030452-0.
29. Sahm DF, Kissinger J, Gilmore MS, Murray PR, Mulder R, Solliday J, Clarke B. 1989. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 33:1588-1591. http://dx.doi.org/10.1128/AAC.33.9.1588.
30. Qin X, Galloway-Pena JR, Sillanpaa J, Roh JH, Nallapareddy SR, Chowdhury S, Bourgogne A, Choudhury T, Muzny DM, Buhay CJ, Ding Y, Dugan-Rocha S, Liu W, Kovar C, Sodergren E, Highlander S, Petrosino JF, Worley KC, Gibbs RA, Weinstock GM, Murray BE. 2012. Complete genome sequence of Enterococcus faecium strain TX16 and comparative genomic analysis of Enterococcus faecium genomes. BMC Microbiol 12:135. http://dx.doi.org/10.1186/1471-2180-12-135.
31. Bernal P, Munoz-Rojas J, Hurtado A, Ramos JL, Segura A. 2007. A Pseudomonas putida cardiolipin synthesis mutant exhibits increased sensitivity to drugs related to transport functionality. Environ Microbiol 9:1135-1145. http://dx.doi.org/10.1111/j.1462-2920.2006.01236.x.
32. Matsumoto K, Kusaka J, Nishibori A, Hara H. 2006. Lipid domains in bacterial membranes. Mol Microbiol 61:1110-1117. http://dx.doi.org/10.1111/j.1365-2958.2006.05317.x.
33. Kawai F, Shoda M, Harashima R, Sadaie Y, Hara H, Matsumoto K. 2004. Cardiolipin domains in Bacillus subtilis Marburg membranes. J Bacteriol 186:1475-1483. http://dx.doi.org/10.1128/JB.186.5.1475-1483.2004.
34. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, Diaz L, Tran TT, Rincon S, Barbu EM, Reyes J, Roh JH, Lobos E, Sodergren E, Pasqualini R, Arap W, Quinn JP, Shamoo Y, Murray BE, Weinstock GM. 2011. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 365:892-900. http://dx.doi.org/10.1056/NEJMoa1011138.
35. Miller C, Kong J, Tran TT, Arias CA, Saxer G, Shamoo Y. 2013. Adaptation of Enterococcus faecalis to daptomycin reveals an ordered progression to resistance. Antimicrob Agents Chemother 57:5373-5383. http://dx.doi.org/10.1128/AAC.01473-13.
36. Tran TT, Panesso D, Gao H, Roh JH, Munita JM, Reyes J, Diaz L, Lobos EA, Shamoo Y, Mishra NN, Bayer AS, Murray BE, Weinstock GM, Arias CA. 2013. Whole-genome analysis of a daptomycin-susceptible Enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob Agents Chemother 57:261-268. http://dx.doi.org/10.1128/AAC.01454-12.
37. Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, Pillai S, Moellering RC, Jr, Eliopoulos GM. 2012. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 7:e28316. http://dx.doi.org/10.1371/journal.pone.0028316.
38. Humphries RM, Kelesidis T, Tewhey R, Rose WE, Schork N, Nizet V, Sakoulas G. 2012. Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 56:6051-6053. http://dx.doi.org/10.1128/AAC.01318-12.
39. Kelesidis T, Tewhey R, Humphries RM. 2013. Evolution of high-level daptomycin resistance in Enterococcus faecium during daptomycin therapy is associated with limited mutations in the bacterial genome. J Antimicrob Chemother 68:1926-1928. http://dx.doi.org/10.1093/jac/dkt117.
40. Kitagawa H, Ozawa T, Takahata S, Iida M, Saito J, Yamada M. 2007. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK. J Med Chem 50: 4710-4720. http://dx.doi.org/10.1021/jm0705354.
41. Zhang YM, Marrakchi H, White SW, Rock CO. 2003. The application of computational methods to explore the diversity and structure of bacterial fatty acid synthase. J Lipid Res 44:1-10. http://dx.doi.org/10.1194/jlr.R200016-JLR200.
42. Marrakchi H, Dewolf WE, Jr, Quinn C, West J, Polizzi BJ, So CY, Holmes DJ, Reed SL, Heath RJ, Payne DJ, Rock CO, Wallis NG. 2003. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK). Biochem J 370:1055-1062. http://dx.doi.org/10.1042/BJ20021699.
43. Heath RJ, Rock CO. 2000. A triclosan-resistant bacterial enzyme. Nature 406:145-146. http://dx.doi.org/10.1038/35018162.
44. Emerson JE, Stabler RA, Wren BW, Fairweather NF. 2008. Microarray analysis of the transcriptional responses of Clostridium difficile to environmental and antibiotic stress. J Med Microbiol 57:757-764. http://dx.doi.org/10.1099/jmm.0.47657-0.
45. Langklotz S, Baumann U, Narberhaus F. 2012. Structure and function of the bacterial AAA protease FtsH. Biochim Biophys Acta 1823:40-48. http://dx.doi.org/10.1016/j.bbamcr.2011.08.015.
46. Bove P, Capozzi V, Garofalo C, Rieu A, Spano G, Fiocco D. 2012. Inactivation of the ftsH gene of Lactobacillus plantarum WCFS1: effects on growth, stress tolerance, cell surface properties and biofilm formation. Microbiol Res 167:187-193. http://dx.doi.org/10.1016/j.micres.2011.07.001.
47. Deuerling E, Mogk A, Richter C, Purucker M, Schumann W. 1997. The ftsH gene of Bacillus subtilis is involved in major cellular processes such as sporulation, stress adaptation and secretion. Mol Microbiol 23:921-933. http://dx.doi.org/10.1046/j.1365-2958.1997.2721636.x.
48. Zellmeier S, Zuber U, Schumann W, Wiegert T. 2003. The absence of FtsH metalloprotease activity causes overexpression of the sigma W-controlled pbpE gene, resulting in filamentous growth of Bacillus subtilis. J Bacteriol 185:973-982. http://dx.doi.org/10.1128/JB.185.3.973-982.2003.
49. Wehrl W, Niederweis M, Schumann W. 2000. The FtsH protein accumulates at the septum of Bacillus subtilis during cell division and sporulation. J Bacteriol 182:3870-3873. http://dx.doi.org/10.1128/JB.182.13.3870-3873.2000.
50. Fibriansah G, Kovacs AT, Pool TJ, Boonstra M, Kuipers OP, Thunnissen AM. 2012. Crystal structures of two transcriptional regulators from Bacillus cereus define the conserved structural features of a PadR subfamily. PLoS One 7:e48015. http://dx.doi.org/10.1371/journal.pone.0048015.
51. Madoori PK, Agustiandari H, Driessen AJ, Thunnissen AM. 2009. Structure of the transcriptional regulator LmrR and its mechanism of multidrug recognition. EMBO J 28:156-166. http://dx.doi.org/10.1038/emboj.2008.263.
52. Agustiandari H, Lubelski J, van den Berg van Saparoea HB, Kuipers OP, Driessen AJ. 2008. LmrR is a transcriptional repressor of expression of the multidrug ABC transporter LmrCD in Lactococcus lactis. J Bacteriol 190:759-763. http://dx.doi.org/10.1128/JB.01151-07.
53. Agustiandari H, Peeters E, de Wit JG, Charlier D, Driessen AJ. 2011. LmrR-mediated gene regulation of multidrug resistance in Lactococcus lactis. Microbiology 157:1519-1530. http://dx.doi.org/10.1099/mic.0.048025-0.
54. Lubelski J, de Jong A, van Merkerk R, Agustiandari H, Kuipers OP, Kok J, Driessen AJ. 2006. LmrCD is a major multidrug resistance transporter in Lactococcus lactis. Mol Microbiol 61:771-781. http://dx.doi.org/10.1111/j.1365-2958.2006.05267.x.
55. Guan Z, Katzianer D, Zhu J, Goldfine H. 2014. Clostridium difficile contains plasmalogen species of phospholipids and glycolipids. Biochim Biophys Acta 1842:1353-1359. http://dx.doi.org/10.1016/j.bbalip.2014.06.011.
56. Friedman L, Alder JD, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 50:2137-2145. http://dx.doi.org/10.1128/AAC.00039-06.
57. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, Kalbacher H, Nieuwenhuizen WF, Jung G, Tarkowski A, van Kessel KP, van Strijp JA. 2001. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 193: 1067-1076. http://dx.doi.org/10.1084/jem.193.9.1067.
58. Mishra NN, Rubio A, Nast CC, Bayer AS. 2012. Differential adaptations of methicillin-resistant Staphylococcus aureus to serial in vitro passage in daptomycin: evolution of daptomycin resistance and role of membrane carotenoid content and fluidity. Int J Microbiol 2012:683450. http://dx.doi.org/10.1155/2012/683450.
59. Yang SJ, Mishra NN, Rubio A, Bayer AS. 2013. Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob Agents Chemother 57:5658-5664. http://dx.doi.org/10.1128/AAC.01184-13.
60. Rubio A, Conrad M, Haselbeck RJ, Brown-Driver G CKV, Finn J, Silverman JA. 2011. Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus. Antimicrob Agents Chemother 55:364-367. http://dx.doi.org/10.1128/AAC.00429-10.
61. Bao Y, Sakinc T, Laverde D, Wobser D, Benachour A, Theilacker C, Hartke A, Huebner J. 2012. Role of mprF1 and mprF2 in the pathogenicity of Enterococcus faecalis. PLoS One 7:e38458. http://dx.doi.org/10.1371/journal.pone.0038458.
62. Roy H, Ibba M. 2009. Broad range amino acid specificity of RNA-dependent lipid remodeling by multiple peptide resistance factors. J Biol Chem 284:29677-29683. http://dx.doi.org/10.1074/jbc.M109.046367.
63. Ernst CM, Staubitz P, Mishra NN, Yang SJ, Hornig G, Kalbacher H, Bayer AS, Kraus D, Peschel A. 2009. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 5:e1000660. http://dx.doi.org/10.1371/journal.ppat.1000660.
64. Abranches J, Tijerina P, Aviles-Reyes A, Gaca AO, Kajfasz JK, Lemos JA. 2014. The cell wall-targeting antibiotic stimulon of Enterococcus faecalis. PLoS One 8:e64875. http://dx.doi.org/10.1371/journal.pone.0064875.
65. Michaux C, Saavedra LF, Reffuveille F, Bernay B, Goux D, Hartke A, Verneuil N, Giard JC. 2013. Cold-shock RNA-binding protein CspR is also exposed to the surface of Enterococcus faecalis. Microbiology 159: 2153-2161. http://dx.doi.org/10.1099/mic.0.071076-0.
66. Pogliano J, Pogliano N, Silverman JA. 2012. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol 194:4494-4504. http://dx.doi.org/10.1128/JB.00011-12.
67. Tran TT, Panesso D, Mishra NN, Mileykovskaya E, Guan Z, Munita JM, Reyes J, Diaz L, Weinstock GM, Murray BE, Shamoo Y, Dowhan W, Bayer AS, Arias CA. 2013. Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. mBio 4(4):pii:e00281-13. http://dx.doi.org/10.1128/mBio.00281-13.
68. Mascher T, Margulis NG, Wang T, Ye RW, Helmann JD. 2003. Cell wall stress responses in Bacillus subtilis: the regulatory network of the bacitracin stimulon. Mol Microbiol 50:1591-1604. http://dx.doi.org/10.1046/j.1365-2958.2003.03786.x.
69. Wolf D, Kalamorz F, Wecke T, Juszczak A, Mader U, Homuth G, Jordan S, Kirstein J, Hoppert M, Voigt B, Hecker M, Mascher T. 2010. In-depth profiling of the LiaR response of Bacillus subtilis. J Bacteriol 192:4680-4693. http://dx.doi.org/10.1128/JB.00543-10.
70. Jordan S, Junker A, Helmann JD, Mascher T. 2006. Regulation of LiaRS-dependent gene expression in Bacillus subtilis: identification of inhibitor proteins, regulator binding sites, and target genes of a conserved cell envelope stress-sensing two-component system. J Bacteriol 188:5153-5166. http://dx.doi.org/10.1128/JB.00310-06.
71. Diaz L, Tran TT, Munita JM, Miller WR, Rincon S, Carvajal LP, Wollam A, Reyes J, Panesso D, Rojas NL, Shamoo Y, Murray BE, Weinstock GM, Arias CA. 2014. Whole-genome analyses of Enterococcus faecium isolates with diverse daptomycin MICs. Antimicrob Agents Chemother 58:4527-4534. http://dx.doi.org/10.1128/AAC.02686-14.
72. Munita JM, Panesso D, Diaz L, Tran TT, Reyes J, Wanger A, Murray BE, Arias CA. 2012. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 56:4354-4359. http://dx.doi.org/10.1128/AAC.00509-12.
73. Hachmann AB, Angert ER, Helmann JD. 2009. Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin. Antimicrob Agents Chemother 53:1598-1609. http://dx.doi.org/10.1128/AAC.01329-08.
74. Goldfine H. 2010. The appearance, disappearance and reappearance of plasmalogens in evolution. Prog Lipid Res 49:493-498. http://dx.doi.org/10.1016/j.plipres.2010.07.003.
75. Drucker DB, Wardle HM, Boote V. 1996. Phospholipid profiles of Clostridium difficile. J Bacteriol 178:5844-5846.
76. Portela CA, Smart KF, Tumanov S, Cook GM, Villas-Boas SG. 2014. Global metabolic response of Enterococcus faecalis to oxygen. J Bacteriol 196:2012-2022. http://dx.doi.org/10.1128/JB.01354-13.